Apelin-17 vs Vasostatin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Apelin-17 is a 17-amino acid C-terminal fragment of the prepro-apelin precursor that binds and activates the APJ receptor (now APLNR) with the highest potency of all naturally occurring apelin isoforms. While apelin-13 is the best-characterized isoform, apelin-17 shows greater re...
Calculate Apelin-17 dose →Vasostatin refers to the N-terminal fragments of chromogranin A (CgA), particularly CgA1-76 (Vasostatin-1) and CgA1-113 (Vasostatin-2), generated by proteolytic processing of the chromogranin A precursor. While catestatin (CgA352-372) is the C-terminal CgA fragment with anti-cate...
Calculate Vasostatin dose →| Parameter | Apelin-17 | Vasostatin |
|---|---|---|
| Category | Cardiovascular Peptide | Cardiovascular Peptide |
| Research | Preclinical / Phase I | Preclinical Research |
| Half-Life | ~3-5 minutes IV (longer than apelin-13) | ~20-30 minutes (estimated) |
| Typical Dose | 30-100 nmol/kg/min (IV infusion, clinical) | 0.1-10 nmol/kg IV (animal) |
| Frequency | Acute infusion protocols | Acute dosing |
| Route | IV infusion (clinical studies); SC under investigation | IV (research) |
| FDA Status | Investigational (Phase I/II) | Research compound |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.